Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-20-020289
Filing Date
2020-07-23
Accepted
2020-07-23 21:24:36
Documents
2
Period of Report
2020-07-23

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 4832
2 EX-24.1 DOCUMENT attachment1.htm EX-24.1 4604
  Complete submission text file 0000899243-20-020289.txt   10892
Mailing Address ONE UNIVERSITY SQUARE DRIVE, SUITE 280 PRINCETON NJ 08540
Business Address
Bjarke Henric Bjorn (Reporting) CIK: 0001652179 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39397 | Film No.: 201044894

Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Issuer) CIK: 0001693011 (see all company filings)

EIN.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations